#delzota
LightNews LightNews
theakarifoundation.bsky.social
📣 Avidity Biosciences Comunica:

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #AvidityBiosciences #delzota #EXPLORE44 #EXPLORE44OLE #somoselcorazóndeladistrofia #AkariJulio
July 23, 2025 at 7:27 PM
theakarifoundation.bsky.social
🔗Lee el artículo completo en el siguiente link: theakarifoundation-pr.org/blog/

Da clic en el link de nuestro perfil y visita nuestros BLOGS más recientes

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DMD #AvidityBiosciences #delzota #EXPLORE44 #EXPLORE44OLE #AkariJulio
July 24, 2025 at 12:50 AM
dmdwarrior.com
Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial

#dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences

👉 Read More: DMDWarrioR.com
Del-zota (Exon 44 Skipping Therapy) Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in Phase 1/2 Trial With del-zota, normal dystrophin increased by 25% and creatine kinase decreased by 80%. Among exon 44 skipping therapies, the highest values ​​currently received have caused excitement. Unprecedented rapid reduction in creatine kinase (CK) to near normal levels maintained over 16 months of follow-up and 25% increase of normal in dystrophin production, reflecting sustained muscle fiber protection.
September 10, 2025 at 12:27 PM
dmdwarrior.com
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

#dmd #duchenne #delzota #exon44 #exon44skipping #clinicaltrials #aviditybiosciences

👉 Read More: DMDWarrioR.com
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
October 13, 2025 at 1:28 PM